Global /China /Healthcare /Biotechnology /002038
chevron_leftBack
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd.

002038
SHE: 002038 Delayed
6.49CNY -3.9%
0.9590 USD
As of 15 June 2026, Beijing SL Pharmaceutical Co., Ltd. has a market cap of $983.99M USD, ranking #10798 globally and #3034 in China. It ranks #964 in the Healthcare sector, and #184 in the Biotechnology industry.
Global Rank
10798
Country Rank
3034
Sector Rank
964
Industry Rank
184
Key Stats
Market Cap
$983.99MUSD
6.67B CNY
Enterprise Value
$835.82MUSD
5.66B CNY
Revenue (TTM)
$92.04MUSD
623.64M CNY
EBITDA (TTM)
$24.25MUSD
164.13M CNY
Net Income (TTM)
-$51.24MUSD
-347.2M CNY
EBITDA Margin
26%
Profit Margin
-56%
PS Ratio
10.7
PB Ratio
1.3
EV/EBITDA
34.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Mingbo Xu open_in_new
Employees
889
Founded
1994
Website
slpharm.com.cn open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-3.9% -8.3% 2.1% -13% -9.9% 4.8%

News

Loading...

Markets

Exchange Ticker Price
Shenzhen Stock Exchange
MIC: XSHE
PRIMARY
002038
北京双鹭药业股份有限公司 Class A
ISIN: CNE000001L31
Shares Out.:
851.913M1 Shares Float: 593.786M2
TV:
SA:
YF:
GF:
BA:
MS:
6.49 CNY
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Beijing SL Pharmaceutical Co., Ltd.

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People’s Republic of China and internationally. The company’s finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; pegylated human granulocyte-stimulating factor injection; human granulocyte-cell stimulating factor injection; recombinant human basic fibroblast growth factor for external use recombinant human basic fibroblast growth factor gel; human interleukin-11; arsenic trioxide; thymopentin; paclitaxel injection; docetaxel injection; vinorelbine tartrate injection; asparaginase; calcium folinate; gemcitabine hydrochloride; regorafenib tablets; oseltamivir phosphate capsules; ornidazole injection; adefovir dipivoxil capsules/adefovir dipivoxil tablets; ribavirin; valacyclovir hydrochloride; levofloxacin hydrochlorid; tenofovir disoproxil fumarate; cyclosporin injection/cyclosporin soft capsules; mycophenolate mofetil dispersible; coenzyme complex; enoxaparin sodium; simvastatin; telmisartan amlodipine; liposon; nitroglycerin spray; eptifibatide, argatroban; voglibose; dapagliflozin; vildagliptin; granisetron hydrochloride injection; omeprazole enteric-coated capsules; adenosylmethionine butanedisulfonate; cytidine triphosphate disodium injection cytidine triphosphate disodium injection; gabapentin; risedronate sodium; salmon calcitonin injection; lucosamine sulfate capsules; loratadine dispersible; desloratadine; naftopidil; somatostatin for injection; octreotide acetate; and etodolac sustained-release tablets. The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998. Beijing SL Pharmaceutical Co., Ltd. was founded in 1994 and is headquartered in Beijing, the People’s Republic of China.

Similar Companies

Industry: Biotechnology (China)
Name
Market Cap diff.
PE
$17.44B
136.71B HKD
2K%
25.3
$12.2B
95.58B HKD
1K%
22.1
$8.0B
54.23B CNY
713%
34.4
$7.33B
49.69B CNY
645%
-
1530
$7.08B
55.5B HKD
620%
5.8
$6.72B
45.52B CNY
583%
61.6
Industry: Biotechnology (Global)
Name
Market Cap diff.
PE
AMGN
$182.42B
18K%
23.9
GILD
$159.92B
16K%
19.0
ARGX
$47.84B
41.39B EUR
5K%
39.9
$44.84B
68.19T KRW
4K%
35.5
CSL
$42.36B
60.27B AUD
4K%
29.3
LONN
$42.3B
33.71B CHF
4K%
37.2
chevron_leftBack